Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novocure Limited (NASDAQ: NVCR) SEC filings page on Stock Titan provides access to the company’s official disclosures as a registrant under U.S. securities laws. Novocure is incorporated in Jersey and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37565. These filings document material events, financial performance and regulatory updates related to its Tumor Treating Fields (TTFields) oncology business.
Among the key documents available are Form 8-K current reports, which Novocure uses to announce items such as quarterly financial results, clinical trial decisions and regulatory milestones. Recent 8-K filings reference press releases on net revenues, active patient counts on TTFields therapy, and the termination of the LUNAR-4 trial, as well as regulatory approvals like Japan’s Ministry of Health, Labour and Welfare decision on Optune Lua for certain NSCLC patients.
Investors and researchers can also use this page to monitor periodic reports such as annual and quarterly filings when available, which typically include consolidated financial statements, details on research, development and clinical study expenses, and discussions of sales, marketing and general and administrative costs. These documents provide structured insight into Novocure’s TTFields-based product portfolio, including Optune Gio and Optune Lua, and the company’s spending on clinical and regulatory programs in glioblastoma, non-small cell lung cancer, mesothelioma and pancreatic cancer.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand changes in revenue, operating expenses, cash position and key clinical or regulatory disclosures. Users can also review insider and management-related filings such as Forms 3, 4 and 5 when available, to track equity transactions by directors and officers.
With real-time updates from EDGAR and AI-assisted explanations, this page serves as a focused resource for analyzing Novocure’s regulatory record, financial condition and material events that shape its TTFields oncology platform.
NovoCure Limited filed an amendment to a prior report to describe the compensation package for its new Chief Executive Officer, Frank Leonard, whose appointment became effective December 1, 2025. A new employment agreement, effective January 1, 2026, sets an annual base salary of CHF 750,000 and a discretionary annual cash bonus targeted at 90% of base salary, based on performance goals set by the Board.
Leonard is eligible for equity awards under the 2024 Omnibus Incentive Plan and broad executive benefits, including relocation reimbursement from the U.S. to Switzerland and six months of COBRA reimbursements, each grossed up for taxes. He also receives tax indemnification if U.S. federal and Pennsylvania authorities do not fully credit Swiss tax payments. If terminated without cause or if he resigns for good reason before a change in control, he is entitled to one year of base salary paid in installments. If such a termination occurs within 12 months after a change in control, he is entitled to a lump sum of 200% of base salary plus 200% of target bonus, and all equity awards will fully vest. The agreement includes perpetual non-disparagement and 12‑month post-employment confidentiality, non-compete, and non-solicitation covenants.
NovoCure Limited is asking shareholders to vote at its June 3, 2026 annual meeting on four main items: electing 11 directors for one-year terms, ratifying EY Global as auditor for 2026, approving a non-binding Say-on-Pay vote, and amending its 2024 Omnibus Incentive Plan.
The amended plan would increase the share reserve by 9,000,000 Ordinary Shares, extend the plan’s term to 2036, remove liberal share recycling, and introduce a general one-year minimum vesting requirement, with limited exceptions. As of the April 6, 2026 record date, NovoCure had 115,820,940 Ordinary Shares outstanding, 2,879,680 shares remaining available under the current plan, and 21,234,241 shares subject to outstanding awards, implying total overhang of 22.2% if the increase is approved.
The company highlights 2025 progress: $655 million in net revenue (up 8%), 4,620 active TTFields patients (up 12%), 7,035 prescriptions (up 9%), key Phase 3 PANOVA-3 and METIS trial successes leading to FDA submissions, and cash, cash equivalents and short-term investments of $448 million at year-end. The Board reports strong independence, diversity metrics, and broad-based equity participation, and recommends voting FOR all proposals.
NovoCure Limited reported a change to executive compensation as Uri Weinberg, M.D., Ph.D. takes on the additional role of Chief Medical Officer while continuing as Chief Innovation Officer. Under a letter agreement dated April 7, 2026, he will receive a stipend increasing his salary by CHF 5,000 per month for as long as he serves as Chief Medical Officer. The company states this additional amount is tied solely to the extra assignment and will not be included when calculating his annual incentive payment, while all other employment terms remain unchanged.
The Vanguard Group filed an amendment to a Schedule 13G/A reporting beneficial ownership of 0 shares of Novocure Ltd Common Stock, representing 0% of the class.
The filing states that on January 12, 2026 Vanguard completed an internal realignment and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim and dated 03/26/2026.
Novocure reported positive topline Phase 2 PANOVA-4 results for Tumor Treating Fields (TTFields) used with atezolizumab, gemcitabine and nab-paclitaxel as first-line therapy for metastatic pancreatic ductal adenocarcinoma.
The regimen achieved a disease control rate of 74.4% in 78 patients, compared with 48% in 431 patients receiving gemcitabine and nab-paclitaxel alone in a historical Phase 3 control, a 26.4% difference with strong statistical significance (1-sided p < 0.001). Objective response rate was 34.6% and median overall survival was 9.7 months. Treatment duration and safety for TTFields were consistent with prior studies, and the company plans to present additional data at a future scientific forum.
NovoCure Ltd former Chief Medical Officer Nicolas Leupin reported an open-market sale of 1,100 Ordinary Shares on March 4, 2026 at a weighted average price of $13.3054 per share. According to the disclosure, this sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. Following this transaction, Leupin directly held 102,979 Ordinary Shares.
NovoCure Ltd reported that former Chief Executive Officer Ashley Cordova had 17,638 ordinary shares withheld on March 4, 2026 to cover tax obligations tied to vesting Restricted Stock Units. The shares were withheld by the issuer at $13.30 per share in a non-discretionary, tax-withholding disposition. After this transaction, Cordova directly owned 422,570 ordinary shares.
NovoCure Ltd reported that its General Counsel, Ben Arye Barak, received new equity awards. He was granted stock options for 73,340 ordinary shares at an exercise price of $0.00 per share, bringing his total options reported in this line to 73,340.
He also acquired 50,125 ordinary shares in the form of restricted share units at $0.00 per share, increasing his directly held ordinary shares to 242,453. The restricted share units are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the grant date, subject to his continued employment. The options are scheduled to vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date, also subject to continued employment.
NovoCure Ltd chief medical and innovation officer Uri Weinberg reported several equity transactions. He sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding tied to restricted stock unit vesting, a sale mandated by the company’s equity plan. Following this sale, he held 267,190 ordinary shares. Weinberg also received 50,125 ordinary shares as a grant of restricted share units and 73,340 stock options, both at a grant price of $0.00. The restricted share units are scheduled to vest in three equal parts on the first, second, and third anniversaries of the grant date, while the stock options vest in four equal parts on the first through fourth anniversaries, each subject to his continued employment.
NovoCure Ltd Chief Financial Officer Christoph Brackmann reported a mix of equity grants and a small mandated share sale. He received 55,137 ordinary shares as a restricted stock award, which are scheduled to vest in equal parts on the first, second and third anniversaries of the grant date, subject to continued employment.
He was also granted options over 80,674 ordinary shares, vesting in equal parts on the first through fourth anniversaries, subject to continued employment. In connection with restricted stock unit vesting, he sold 6,412 ordinary shares at a weighted average price of $13.3054 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement, leaving 182,842 ordinary shares held directly afterward.